Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes
Status:
Terminated
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the effect of rimonabant 20 mg daily when
added to ongoing metformin therapy on glycemic control (HbA1c) over a 36 week period in
patients with type 2 diabetes.
Secondary objectives include evaluation of other markers of glycemic control, lipid profile,
body weight, and abdominal obesity. Also, the trial will study the safety of rimonabant when
added to metformin over a period of 47 weeks.